Sanofi loses challenge to Amgen patents for cholesterol-busting Repatha

Intellectual Property 2025-04-23 1:13 pm By Christine Caulfield

Please login to bookmark

Drug giant Sanofi has failed in its appeal of a decision granting applications by biopharmaceutical company Amgen for patents covering the cholesterol-lowering treatment Repatha.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au